Citations

Institution: Mayo Clinic Clear

Showing 10 of 108135 citations.

TO VAD OR NOT TO VAD
Friedman, Emily, McMahon, Molly

Proceedings of the International Symposium on Human Factors and Ergonomics in Health Care | July 22, 2014 | Volume: 3 | Issue: 1 | Pages: 238-245

10.1177/2327857914031039 Get It

As part of its Healthy Aging & Independent Living (HAIL) initiative, Mayo Clinic Center for Innovation (CFI) examined the patient experience regarding the decision to receive a ventricular assistive device (VAD) implant, and patients’ quality of life after the surgery. As health care technology continues to develop, more people will be living longer, fuller lives with the assistance of wearable/implantable medical devices such as the VAD. This case study examined and made recommendations on ways for the Mayo Clinic VAD Committee to improve the program.
Faculty Opinions recommendation of Characterization of women with elevated antimüllerian hormone levels (AMH): correlation of AMH with polycystic ovarian syndrome phenotypes and assisted reproductive technology outcomes.
Coddington, Charles C.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature | July 22, 2014 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.3410/f.718300943.793497505 Get It

Two‐Dimensional Measurement of Tricuspid Annular Plane Systolic Excursion in Children: Can It Substitute for an M‐Mode Assessment?
Qureshi, M. Yasir , Eidem, Benjamin W., Reece, Chelsea L., Qureshi, Muhammad Yasir, O’Leary, Patrick , Qureshi, Muhammad Y

Echocardiography | July 22, 2014 | Volume: 32 | Issue: 3 | Pages: 528-534

10.1111/echo.12687 | PMID 25048993 Get It

BackgroundTricuspid annular plane systolic excursion measured by M‐mode (MM‐TAPSE) has been validated as a marker of right ventricular systolic performance. A similar measurement by 2D imaging (2D‐TAPSE) can be obtained. We sought to determine the correlation and strength of agreement between MM‐TAPSE and 2D‐TAPSE in children.MethodsEchocardiographic studies performed for clinical indications were reviewed retrospectively. All consecutive subjects ≤18 years of age were included. The cohort was divided into those with normal echocardiographic findings and those with disorders affecting the right ventricle. Digitally recorded images were analyzed for both MM‐TAPSE and 2D‐TAPSE. Measurements of 2D‐TAPSE were made in an apical four‐chamber view, from the tricuspid valve annulus to a consistent point at the apex of the imaging sector at end‐diastole and end‐systole, with the difference representing the 2D‐TAPSE value.ResultsA total of 329 subjects (mean age 9.0 ± 6.1 years) met entry criteria. Correlation coefficient between MM‐TAPSE and 2D‐TAPSE was 0.90. Bland–Altman analysis showed agreement between the two methods to be within 1.2 ± 2.6 mm (mean percentage difference of 6.5%). About 1 mm difference between MM‐TAPSE and 2D‐TAPSE was consistently observed in all diagnostic subgroups, and across all age categories.ConclusionMM‐TAPSE and 2D‐TAPSE correlate strongly, with 2D‐TAPSE being consistently about 1 mm less than values obtained by the M‐mode technique. We conclude that 2D‐TAPSE can provide a reliable alternative to MM‐TAPSE to quantitatively measure right ventricular systolic function and may be especially useful in situations where retrospective comparisons are sought.
Preserved Function of Late-Outgrowth Endothelial Cells in Medically Treated Hypertensive Patients Under Well-Controlled Conditions
Herrmann, Sandra M. , Zhu, Xiangyang , Jordan, Kyra L., Gloviczki, Monika L. , Textor, Stephen C., Lerman, Lilach O. , Chen, Zhi , Herrmann, Sandra M S, Chen, Zhi , Lerman, Amir , Herrmann, Sandra M

Hypertension | July 22, 2014 | Volume: 64 | Issue: 4 | Pages: 808-814

10.1161/hypertensionaha.114.03720 | PMID 25047576 Get It

Endothelial progenitor cells (EPCs) participate in renal repair, but their number and function may be impaired by exposure to cardiovascular risk factors. The number of circulating EPCs is decreased in essential and renovascular hypertensive patients, but the effects of hypertension on EPC function are incompletely understood. We hypothesized that EPC function was preserved under well-controlled conditions in treated hypertensive patients. Patients with atherosclerotic renal artery stenosis (ARAS; n=22) or essential hypertension (n=24) were studied during controlled sodium intake and antihypertensive regimen. Late-outgrowth EPCs were isolated from the inferior vena cava (IVC) and renal vein blood of ARAS and essential hypertension patients and a peripheral vein of matched normotensive controls (n=18). The angiogenic function of EPCs was assessed in vitro, and multidetector computed tomography was used to measure single-kidney hemodynamics and function in ARAS and essential hypertension patients. Inflammatory biomarkers and EPC homing signal levels and renal release were calculated. Inferior vena cava and renal vein–obtained EPC function were similar in ARAS and essential hypertension patients and comparable to that in normal controls (tube length, 171.86±16.846, 191.09±14.222, 174.925±19.774 μm, respectively). Function of renal vein–obtained EPCs directly correlated with stenotic kidney glomerular filtration rate, EPC homing factors, and anti-inflammatory mediator levels in ARAS patients. Therefore, EPC function was relatively preserved in ARAS patients, although it directly correlated with renal function. Adequate EPC function supports the feasibility of using autologous EPCs as a therapeutic option in essential and renovascular hypertensive patients. Homing signals and inflammatory mediators may potentially regulate EPC angiogenic function.
Oncology Fellows' Career Plans, Expectations, and Well-Being: Do Fellows Know What They Are Getting Into?
Raymond, Marilyn, Horn, Leora , Moynihan, Tim, Collichio, Frances A. , Chew, Helen K. , Kosty, Michael P., Satele, Daniel , Sloan, Jeff A. , Gradishar, William J. , Shanafelt, Tait D.

Journal of Clinical Oncology | July 21, 2014 | Volume: 32 | Issue: 27 | Pages: 2991-2997

10.1200/jco.2014.56.2827 | PMID 25049326 Get It

Purpose To evaluate the career plans, professional expectations, and well-being of oncology fellows compared with actual experiences of practicing oncologists. Methods US oncology fellows taking the 2013 Medical Oncology In-Training Examination (MedOnc ITE) were invited to participate in an optional postexamination survey. The survey evaluated fellows' career plans and professional expectations and measured burnout, quality of life (QOL), fatigue, and satisfaction with work-life balance (WLB) using standardized instruments. Fellows' professional expectations and well-being were compared with actual experiences of US oncologists assessed simultaneously. Results Of the 1,637 oncology fellows in the United States, 1,373 (83.9%) took the 2013 MedOnc ITE. Among these, 1,345 (97.9%) completed the postexamination survey. The frequency of burnout among fellows decreased from 43.3% in year 1 to 31.7% in year 2 and 28.1% in year 3 (P < .001). Overall, the rate of burnout among fellows and practicing oncologists was similar (34.1% v 33.7%; P = .86). With respect to other dimensions of well-being, practicing oncologists had lower fatigue (P < .001) and better overall QOL scores (P < .001) than fellows but were less satisfied with WLB (P = .0031) and specialty choice (P < .001). Fellows' expectations regarding future work hours were 5 to 6 hours per week fewer than oncologists' actual reported work hours. Levels of burnout (P = .02) and educational debt (P ≤ .004) were inversely associated with ITE scores. Fellows with greater educational debt were more likely to pursue private practice and less likely to plan an academic career. Conclusion Oncology fellows entering practice trade one set of challenges for another. Unrealized expectations regarding work hours may contribute to future professional dissatisfaction, burnout, and challenges with WLB.
Central neurogenic hyperventilation
Kramer, Christopher L., Wijdicks, Eelco F. M.

Neurology | July 21, 2014 | Volume: 83 | Issue: 4 | Pages: 376-376

10.1212/wnl.0000000000000624 | PMID 25049304 Get It

African American Women's Perceptions and Attitudes Regarding Participation in Medical Research: The Mayo Clinic/The Links, Incorporated Partnership
Brewer, LaPrincess C. , Hayes, Sharonne N. , Parker, Monica W. , Balls‐Berry, Joyce E. , Halyard, Michele Y. , Pinn, Vivian W. , Breitkopf, Carmen Radecki , Balls-Berry, Joyce Joy E , Hayes, Sharonne N , Brewer, LaPrincess C

Journal of Women's Health | July 21, 2014 | Volume: 23 | Issue: 8 | Pages: 681-687

10.1089/jwh.2014.4751 | PMID 25046058 Get It

Objective: To examine perceptions and attitudes toward health-related research participation among professional African American women. Methods: Participants were members of an African American women's service organization, The Links, Incorporated. Data were collected via self-administered questionnaires at The Links, Incorporated 2012 National Assembly. Sociodemographics, prior research experience, intention to participate (ITP), willingness to participate (WTP) in a variety of research studies and attitudes about research participation were measured. Results: A total of 381 surveys were analyzed. A majority of respondents were married (66%), employed (69%), and college educated (96%). Median age was 59; 38% reported prior research participation. Overall, 78% agreed with the statement, “Participation in research will mean better care,” 24% agreed “Participation in research is risky” and 3% agreed “Scientists cannot be trusted.” Fifty-two percent agreed with the statement, “Research conducted in the U.S. is ethical.” Mean ITP in research was 4.9±1.7 on a rating scale of 1 (“definitely no”) to 7 (“definitely yes”). WTP was highest for an interview study and providing a blood sample, and lowest for clinical trial and medical record review. Conclusion: Attitudes toward research participation were generally favorable among professional African American women; many expressed WTP in a variety of research study types.
Effects of Adeno-Associated Virus Serotype and Tissue-Specific Expression on Circulating Biomarkers of Propionic Acidemia
Guenzel, Adam J. , Hillestad, Matthew L. , Matern, Dietrich , Barry, Michael A. , Barry, Michael A

Human Gene Therapy | July 21, 2014 | Volume: 25 | Issue: 9 | Pages: 837-843

10.1089/hum.2014.012 | PMID 25046265 Get It

Propionic acidemia (PA) is an autosomal recessive inborn error of metabolism caused by deficiency of propionyl-CoA carboxylase (PCC). This enzyme is composed of six PCCA and six PCCB subunits and mediates a critical step in catabolism of odd chain fatty acids and certain amino acids. Current treatment options for PA are limited to stringent dietary restriction of protein consumption and some patients undergo elective liver transplantation. We previously generated a hypomorphic model of PA, designated Pcca −/− (A138T), with 2% of wild-type enzyme activity that mimics many aspects of the human disease. In this study, we used the differing tissue tropisms of adeno-associated virus (AAV) to probe the ability of liver or muscle-directed gene therapy to treat systemic aspects of this disease that affects many cell types. Systemic therapy with muscle-biased AAV1, liver-biased AAV8, and broadly tropic AAVrh10 mediated significant biochemical corrections in circulating propionylcarnitine (C3) and methyl citrate by all vectors. The innate tissue bias of AAV1 and AAV8 gene expression was made more specific by the use of muscle-specific muscle creatine kinase (specifically MCK6) and hepatocyte-specific transthyretin (TTR) promoters, respectively. Under these targeted conditions, both vectors mediated significant long-term correction of circulating metabolites, demonstrating that correction of muscle and likely other tissue types in addition to liver is necessary to fully correct pathology caused by PA. Liver-specific AAV8-TTR-PCCA mediated better correction than AAV1-MCK-PCCA. These data suggest that targeted gene therapy may be a viable alternative to liver transplantation for PA. They also demonstrate the effects of tissue-specific and broad gene therapy on a cell autonomous systemic genetic disease.
Rituximab for the Treatment of Relapses in Antineutrophil Cytoplasmic Antibody–Associated Vasculitis
Miloslavsky, Eli M. , Seo, Philip , Langford, Carol A. , Hoffman, Gary S., Kallenberg, Cees G. M., Clair, E. William St. , Tchao, Nadia K., Viviano, Lisa, Ding, Linna , Iklé, David , Villarreal, Miguel, Jepson, Brett , Brunetta, P., Allen, Nancy B., Keogh, Karina A., Peikert, Tobias, Stegeman, Coen A. , Ytterberg, Steven R. , Stone, John H., Brunetta, Paul , Specks, Ulrich , Merkel, Peter A. , Spiera, Robert , Fervenza, Fernando C. , Geetha, Duvuru , Kissin, Eugene Y. , Monach, Paul A.

Arthritis & Rheumatology | July 21, 2014 | Volume: 66 | Issue: 11 | Pages: 3151-3159

10.1002/art.38788 | PMID 25047592 Get It

ObjectiveDisease relapses are frequent in antineutrophil cytoplasmic antibody–associated vasculitis (AAV). This study was undertaken to evaluate outcomes in patients with AAV who are re‐treated with rituximab (RTX) and prednisone for severe disease relapses.MethodsThe Rituximab in AAV trial was a randomized, double‐blind, placebo‐controlled trial comparing the rates of remission induction among patients treated with RTX (n = 99) and patients treated with cyclophosphamide (CYC) followed by azathioprine (AZA) (n = 98). Prednisone was tapered to discontinuation after 5.5 months. After remission was achieved, patients who experienced a severe disease relapse between months 6 and 18 were eligible to receive RTX and prednisone on an open‐label basis according to a prespecified protocol. Investigators remained blinded with regard to the original treatment assignment.ResultsTwenty‐six patients received RTX for disease relapse after remission had initially been achieved with their originally assigned treatment. Fifteen of these patients were initially randomized to receive RTX and 11 to receive CYC/AZA. Thirteen (87%) of the patients originally assigned to receive RTX and 10 (91%) originally assigned to receive CYC/AZA achieved remission again with open‐label RTX (an overall percentage of 88%). In half of the patients treated with open‐label RTX, prednisone could be discontinued entirely. Patients in this cohort experienced fewer adverse events compared to the overall study population (4.7 adverse events per patient‐year versus 11.8 adverse events per patient‐year).ConclusionRe‐treatment of AAV relapses with RTX and glucocorticoids appears to be a safe and effective strategy, regardless of previous treatment.
Immunotherapy trial as diagnostic test in evaluating patients with presumed autoimmune gastrointestinal dysmotility
Flanagan, Eoin P. , Saito, Y. A., Lennon, Vanda A. , McKeon, Andrew , Fealey, Robert D., Szarka, Lawrence A., Foxx–Orenstein, Amy E., Fox, Jean C. , Pittock, Sean J. , Saito, Y. A., Murray, Joseph A. , Pittock, S J , Flanagan, E P , McKeon, Andrew

Neurogastroenterology & Motility | July 21, 2014 | Volume: 26 | Issue: 9 | Pages: 1285-1297

10.1111/nmo.12391 | PMID 25039328 Get It

AbstractBackgroundChronic gastrointestinal dysmotility greatly impacts the quality of life. Treatment options are limited and generally symptomatic. Neural autoimmunity is an under‐recognized etiology. We evaluated immunotherapy as an aid to diagnosing autoimmune gastrointestinal dysmotility (AGID).MethodsTwenty‐three subjects evaluated at the Mayo Clinic for suspected AGID (August 2006–February 2014) fulfilled the following criteria: (1) prominent symptoms of gastrointestinal dysmotility with abnormalities on scintigraphy–manometry; (2) serological evidence or personal/family history of autoimmune disease; (3) treated by immunotherapy on a trial basis, 6–12 weeks (intravenous immune globulin, 16; or methylprednisolone, 5; or both, 2). Response was defined subjectively (symptomatic improvement) and objectively (gastrointestinal scintigraphy/manometry studies).Key ResultsSymptoms at presentation: constipation, 18/23; nausea or vomiting, 18/23; weight loss, 17/23; bloating, 13/23; and early satiety, 4/23. Thirteen patients had personal/family history of autoimmunity. Sixteen had neural autoantibodies and 19 had extra‐intestinal autonomic testing abnormalities. Cancer was detected in three patients. Preimmunotherapy scintigraphy revealed slowed transit (19/21 evaluated; gastric, 11; small bowel, 12; colonic, 11); manometry studies were abnormal in 7/8. Postimmunotherapy, 17 (74%) had improvement (both symptomatic and scintigraphic, five; symptomatic alone, eight; scintigraphic alone, four). Nine responders re‐evaluated had scintigraphic evidence of improvement. The majority of responders who were re‐evaluated had improvement in autonomic testing (six of seven) or manometry (two of two).Conclusions & InferencesThis proof of principle study illustrates the importance of considering an autoimmune basis for idiopathic gastrointestinal dysmotility and supports the utility of a diagnostic trial of immunotherapy.